Loading...
•
Dec 31, 2020
Abeona Therapeutics Q4 2020 Earnings Report
Abeona Therapeutics reported financial results for the fourth quarter and full year 2020 and provided an update on recent operational progress.
Key Takeaways
Abeona Therapeutics announced $3.0 million in license and other revenues for the fourth quarter of 2020. Net loss was $15.8 million for the fourth quarter of 2020. Cash, cash equivalents and short-term investments totaled $95.0 million as of December 31, 2020.
Fourth patient treated in pivotal Phase 3 VIITAL™ study of EB-101 in RDEB after successful Type B meeting with FDA
Positive new interim data from MPS IIIA and MPS IIIB programs presented at 17th Annual WORLDSymposium
$95 million in cash, cash equivalents and short-term investments as of December 31, 2020
License and other revenues for the fourth quarter of 2020 were $3.0 million.